A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention (PCI) (CHAMPION PHOENIX)

Inclusion Criteria: Patients may be included in the study if they meet all of the following criteria: * Male or non-pregnant female at least 18 years of age * Patients undergoing percutaneous coronary intervention (PCI): 1. Stable angina (SA) patients with diagnostic coronary angiography within 90 days prior to randomization demonstrating atherosclerosis 2. Non-ST-Segment Elevation Acute Coronary Syndrome (NSTE-ACS) patients with diagnostic coronary angiography within 72 hours prior to randomization demonstrating atherosclerosis 3. ST-segment elevation myocardial infarction (STEMI) patients (diagnostic angiography not required) * Provide written informed consent Exclusion Criteria: Patients will be excluded from the study if any of the following exclusion criteria apply prior to randomization: * Receipt of any P2Y12 inhibitor at any time in the 7 days preceding randomization * Eptifibatide and tirofiban usage within 12 hours preceding randomization (most recent dose must have been administered ≥12 hours prior to randomization) * Abciximab usage within 7 days preceding randomization * Receipt of fibrinolytic therapy in the 12 hours preceding randomization * Increased bleeding risk: ischemic stroke within the last year or any previous hemorrhagic stroke; tumor, cerebral arteriovenous malformation, or intracranial aneurysm; recent (\<1 month) trauma or major surgery (including bypass surgery); currently receiving warfarin; active bleeding